Dishman Carbogen Amcis Ltd. (IN:DCAL)
:DCAL
DCAL Stock Chart & Stats
₹255.15
-₹14.00(-4.80%)
At close: 4:00 PM EST
₹255.15
-₹14.00(-4.80%)
Day’s Range― - ―
52-Week Range₹129.00 - ₹321.15
Previous CloseN/A
Volume578.20K
Average Volume (3M)13.55K
Market Cap
₹23.11B
Enterprise Value₹42.56B
Total Cash (Recent Filing)₹5.32B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.35
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding156,783,100
10 Day Avg. Volume9,637
30 Day Avg. Volume13,551
Financial Highlights & Ratios
PEG Ratio-10.28
Price to Book (P/B)0.58
Price to Sales (P/S)1.25
P/FCF Ratio21.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginAn 81.49% gross margin indicates durable production efficiency and pricing power in CDMO/API operations. High gross margins provide structural buffer against input cost swings, support reinvestment in capacity or R&D, and help sustain operating leverage as revenue scales over months.
Consistent Revenue RecoverySteady top-line growth reflects improving demand and successful project wins in contract services. For a CDMO, sustained revenue growth supports higher capacity utilization and long-duration supply agreements, strengthening predictable cash flows and competitive positioning over the medium term.
Improving Cash Generation & Stable LeverageNear-doubling of free cash flow and manageable debt-to-equity indicate improving cash conversion and financial flexibility. A strong equity base plus rising FCF gives durable capacity to fund capex, service projects, and reduce leverage, enhancing resilience across multi-month cycles.
Bears Say
Extremely Low Net ProfitabilityMinimal net margin and near-zero ROE signal underlying profitability weakness despite strong gross margins. This constrains retained earnings, limits shareholder returns and reinvestment capacity, and leaves the firm vulnerable to smaller revenue declines or cost overruns over the medium term.
Weak Profit-to-cash ConversionOnly half of reported net income converts to free cash flow, implying material working capital, capex, or noncash adjustments. This reduces the reliability of earnings as a funding source, limiting sustainable reinvestment and debt reduction capacity over coming quarters.
Earnings Instability / Prior LossesHistorical losses and a recent recovery point to earnings volatility tied to project timing or one-offs. Such inconsistency complicates long-range planning, risks lumpy cash flows from contract projects, and may impede long-term contractual pricing or customer diversification efforts.
Dishman Carbogen Amcis Ltd. News
DCAL FAQ
What was Dishman Carbogen Amcis Ltd.’s price range in the past 12 months?
Dishman Carbogen Amcis Ltd. lowest stock price was ₹129.00 and its highest was ₹321.15 in the past 12 months.
What is Dishman Carbogen Amcis Ltd.’s market cap?
Dishman Carbogen Amcis Ltd.’s market cap is ₹23.11B.
When is Dishman Carbogen Amcis Ltd.’s upcoming earnings report date?
Dishman Carbogen Amcis Ltd.’s upcoming earnings report date is May 12, 2026 which is in 37 days.
How were Dishman Carbogen Amcis Ltd.’s earnings last quarter?
Dishman Carbogen Amcis Ltd. released its earnings results on Feb 03, 2026. The company reported -₹0.827 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.827.
Is Dishman Carbogen Amcis Ltd. overvalued?
According to Wall Street analysts Dishman Carbogen Amcis Ltd.’s price is currently Overvalued.
Does Dishman Carbogen Amcis Ltd. pay dividends?
Dishman Carbogen Amcis Ltd. pays a Annually dividend of ₹0.2 which represents an annual dividend yield of N/A. See more information on Dishman Carbogen Amcis Ltd. dividends here
What is Dishman Carbogen Amcis Ltd.’s EPS estimate?
Dishman Carbogen Amcis Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dishman Carbogen Amcis Ltd. have?
Dishman Carbogen Amcis Ltd. has 156,783,100 shares outstanding.
What happened to Dishman Carbogen Amcis Ltd.’s price movement after its last earnings report?
Dishman Carbogen Amcis Ltd. reported an EPS of -₹0.827 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.012%.
Which hedge fund is a major shareholder of Dishman Carbogen Amcis Ltd.?
Currently, no hedge funds are holding shares in IN:DCAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dishman Carbogen Amcis Ltd.
Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, intermediates, phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D products, fine chemicals, hand and body wash, sanitisers, antiseptics, and various pharmaceutical and cosmetic-related products, as well as generic and highly potent active pharmaceutical ingredients. The company was incorporated in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Jubilant Ingrevia Ltd.
―
Panacea Biotec Limited
―
Syngene International Ltd.
―